Article
Oncology
Tejus Satish, Shaheer Khan, Matt Levin, Richard Carvajal, Angela J. Yoon
Summary: In this case, a patient with oral mucosal melanoma recurred despite multiple resections and adjuvant temozolomide, but achieved complete histopathologic remission with the combination of topical imiquimod and pembrolizumab, demonstrating the potential efficacy of this combined treatment for oral melanoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Anastasia Prokopi, Christoph H. Tripp, Bart Tummers, Florian Hornsteiner, Sarah Spoeck, Jeremy Chase Crawford, Derek R. Clements, Mirjana Efremova, Katharina Hutter, Lydia Bellmann, Giuseppe Cappellano, Bruno L. Cadilha, Sebastian Kobold, Louis Boon, Daniela Ortner, Zlatko Trajanoski, Suzie Chen, Tanja D. de Gruijl, Juliana Idoyaga, Douglas R. Green, Patrizia Stoitzner
Summary: Immunotherapy with checkpoint inhibitors has shown impressive results in patients with melanoma, but many still do not benefit from this treatment due to factors such as lack of tumor-infiltrating T cells and loss of intratumoral dendritic cells. In a melanoma mouse model, researchers found that tumor progression is characterized by upregulation of checkpoint molecules and gradual loss of dermal conventional DC 2 subset. Monotherapy with checkpoint blockade was not effective, but boosting DC numbers and activation increased tumor immunogenicity, leading to improved T cell function and delayed tumor growth when combined with antibodies against PD-1 and TIM-3. The study highlights the importance of skin DC in cancer immunotherapy and suggests that restoring DC function is key to enhancing tumor immunogenicity and responsiveness to checkpoint blockade therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Oliver John Kennedy, Michal Kicinski, Sara Valpione, Sara Gandini, Stefan Suciu, Christian U. Blank, Georgina Long, Victoria G. Atkinson, Stephane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye Boers-Sonderen, Anna Maria Di Giacomo, Alfonsus J. M. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Caroline Robert, Alexander M. M. Eggermont, Paul Lorigan, Mario Mandala
Summary: This study investigated the prognostic and predictive value of metformin in melanoma, and found that metformin had no significant impact on the efficacy of pembrolizumab, especially in BRAF-mutated melanoma.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Paolo Bossi, Cristina Gurizzan, Luigi Lorini, Pierluigi di Mauro, Chiara Sardini, Marco Merlano
Summary: This paper discusses the potential interplay between myeloid growth factors and the immune system, advocating for further studies to elucidate their possible outcomes when administered in combination with immunotherapeutic agents.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Chemistry, Multidisciplinary
Lijun Yang, Dianyu Wang, Haixue Jia, Cuihong Yang, Yumin Zhang, Hui Li, Jinjian Liu, Jianfeng Liu
Summary: Tumor cells use metabolic reprogramming to create an immunosuppressive tumor microenvironment (TME) and evade the immune system. This study develops a tumor-specific peroxynitrite nanogenerator that disrupts metabolic homeostasis in melanoma cells. The produced peroxynitrite induces a decrease in metabolites in the tricarboxylic acid cycle and reduces lactate production. Mechanistically, peroxynitrite impairs glucose metabolism by affecting the activity of glyceraldehyde-3-phosphate dehydrogenase. These metabolic alterations reverse the immunosuppressive TME and promote antitumor immune responses. When combined with anti-PD-L1, the nanogenerator inhibits both primary and metastatic melanomas without causing toxicity. This research provides a new strategy for enhancing immunotherapy sensitivity.
ADVANCED MATERIALS
(2023)
Article
Oncology
Chenkai Mao, Veronique Beiss, Gregory W. Ho, Jennifer Fields, Nicole F. Steinmetz, Steven Fiering
Summary: This study discovered that ISV with CPMV induces systemic antitumor T-cell-mediated immunity that inhibits growth of untreated tumors and requires conventional type-1 dendritic cells (cDC1s). Furthermore, it was found that combining CPMV with local activation of antigen-presenting cells can enhance antitumor efficacy, induce an influx of CD8(+) T cells, trigger regression in both treated local and untreated distant tumors, and potentiate tumor responses to anti-PD-1 therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Oliver J. Kennedy, Michal Kicinski, Sara Valpione, Sara Gandini, Stefan Suciu, Christian U. Blank, Georgina Long, Victoria G. Atkinson, Stephane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna M. Di Giacomo, Alfonsus J. M. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Caroline Robert, Alexander M. M. Eggermont, Paul Lorigan, Mario Mandala
Summary: This study found that fi-blockers had no independent prognostic effect on resected high-risk stage III melanoma, but they may predict improved efficacy of adjuvant pembrolizumab treatment. Further investigation is warranted for the combination of immunotherapy with fi-blockers.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Biotechnology & Applied Microbiology
Luca Tagliaferri, Valentina Lancellotta, Bruno Fionda, Monica Mangoni, Calogero Casa, Alessandro Di Stefani, Monica Maria Pagliara, Andrea D'Aviero, Giovanni Schinzari, Silvia Chiesa, Ciro Mazzarella, Stefania Manfrida, Giuseppe Ferdinando Colloca, Fabio Marazzi, Alessio Giuseppe Morganti, Maria Antonietta Blasi, Ketty Peris, Giampaolo Tortora, Vincenzo Valentini
Summary: The combination of radiotherapy and immunotherapy shows potential therapeutic effects for melanoma, but further prospective studies are needed to confirm its efficacy.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Oncology
Georgia Sofia Karachaliou, Rached Alkallas, Sarah B. Carroll, Chongshan Caressi, Danny Zakria, Nirali M. Patel, Dimitri G. Trembath, Jennifer A. Ezzell, Guillaume J. Pegna, Paul B. Googe, Jonathan P. Galeotti, Fatih Ayvali, Frances A. Collichio, Carrie B. Lee, David W. Ollila, Margaret L. Gulley, Douglas B. Johnson, Kevin B. Kim, Ian R. Watson, Stergios J. Moschos
Summary: This study found that APC/CTNNB1 gene mutations are associated with worse prognosis and early brain metastases in stage IV melanoma. However, PD-1 inhibitor-based treatments provide comparable benefits to both mutated and wild-type patients with stage IV melanoma.
Article
Oncology
Devarati Mitra, Morgan Farr, Priyadharsini Nagarajan, Joel Ho, Andrew J. Bishop, Anuja Jhingran, Ahsan S. Farooqi, Michael Frumovitz, Rodabe N. Amaria, Jennifer L. McQuade, Amir A. Jazaeri, B. Ashleigh Guadagnolo
Summary: This study examines the patterns of care and oncologic outcomes in patients with gynecologic tract melanoma (GTM). The results show that GTM patients continue to have poor outcomes, particularly in terms of local disease control. More effective oncologic therapy is needed.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Da-Liang Ou, Chia-Wei Chen, Chia-Lang Hsu, Chih-Hung Chung, Zi-Rui Feng, Bin-Shyun Lee, Ann-Lii Cheng, Muh-Hwa Yang, Chiun Hsu
Summary: Regorafenib may enhance antitumor immunity by modulating macrophage polarization independently of its anti-angiogenic effects. It enhances the antitumor effects of antigen-specific T cells and shows synergistic effects with anti-PD1 by affecting multiple immune-related pathways in the tumor microenvironment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Richard A. Miller, Jason John Luke, Shenshen Hu, Suresh Mahabhashyam, William B. Jones, Thomas Marron, Jaime R. Merchan, Brett G. M. Hughes, Stephen B. Willingham
Summary: This study evaluated the effects of Mupadolimab on immune cells and found that it activates B cells and stimulates the production of antigen specific antibodies. These results support further investigation of Mupadolimab as an immunotherapy for cancer and its potential use as a vaccine adjuvant.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Lauren Lukas, Hualin Zhang, Karen Cheng, Alan Epstein
Summary: This review provides an overview of the nontargeted immune effects of spatially fractionated radiation therapy (SFRT) and explores strategies to enhance its immunomodulatory potential in combination with immunotherapy (IT).
CURRENT ONCOLOGY REPORTS
(2023)
Review
Oncology
Luis C. Cabaco, Ana Tomas, Marta Pojo, Duarte C. Barral
Summary: Skin cancers, particularly cutaneous melanoma, are a major health concern worldwide. Despite having a lower incidence, melanoma is the most aggressive form of skin cancer and responsible for the majority of related deaths. Melanin, the pigment produced by melanocytes, plays a central role in the pathology of melanoma. While it provides protection against UV radiation, it also leads to DNA damage and promotes tumor growth. Melanin secretion regulates the invasiveness of melanoma cells and affects the tumor microenvironment and immune responses.
FRONTIERS IN ONCOLOGY
(2022)
Article
Nanoscience & Nanotechnology
Elidamar Nunes de Carvalho Lima, Ana Luiza Moraes Octaviano, Jose Roberto Castilho Piqueira, Ricardo Sobhie Diaz, Joao Francisco Justo
Summary: This study investigates the relationship between immune activation induced by COVID-19 and carbon nanotubes (CNTs), and explores new possibilities of using CNTs as immunotherapeutic agents in the treatment of coronavirus infections.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2022)
Article
Oncology
Paul A. Clark, Raghava N. Sriramaneni, Won Jong Jin, Justin C. Jagodinsky, Amber M. Bates, Abigail A. Jaquish, Bryce R. Anderson, Trang Le, Jonathan A. Lubin, Ishan Chakravarty, Ian S. Arthur, Clinton M. Heinze, Emily Guy, Jasdeep Kler, Kelsey A. Klar, Peter M. Carlson, Kyung Mann Kim, John S. Kuo, Zachary S. Morris
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
Article
Medicine, General & Internal
Lindsay C. Kobayashi, Brendan Q. O'Shea, Jasdeep S. Kler, Raphael Nishimura, Caroline B. Palavicino-Maggio, Marisa R. Eastman, Yamani Rikia Vinson, Jessica M. Finlay
Summary: The COVID-19 Coping Study is a national longitudinal study investigating the impact of pandemic-related stressors on mental health and well-being among middle-aged and older adults. Findings show a significant portion of adults only leaving home for essential purposes, with a proportion of workers being placed on leave or furloughed due to the pandemic. Additionally, a considerable number of individuals screened positive for depression, anxiety, and loneliness.
Article
Oncology
Lauryn R. Werner, Katelin A. Gibson, Merit L. Goodman, Dominika E. Helm, Katherine R. Walter, Sean M. Holloran, Gloria M. Trinca, Richard C. Hastings, Howard H. Yang, Ying Hu, Junping Wei, Gangjun Lei, Xiao-Yi Yang, Rashna Madan, Alfredo A. Molinolo, Mary A. Markiewicz, Prabhakar Chalise, Margaret L. Axelrod, Justin M. Balko, Kent W. Hunter, Zachary C. Hartman, Carol A. Lange, Christy R. Hagan
Summary: Clinical studies have linked the use of progestins, synthetic progesterone, to an increased risk of breast cancer. However, the specific role of native progesterone signaling through the progesterone receptor in breast tumor formation remains poorly understood. Research suggests that progesterone can repress certain immune signaling pathways, potentially promoting tumor development in the mammary gland. This study investigated the effects of progesterone on immune cell populations in mouse mammary glands, as well as the impact of progesterone receptor overexpression on tumor formation and immune cell populations. The findings indicate that progesterone treatment and progesterone receptor overexpression are associated with inhibited immune responses, decreased immune cell populations, and an increased risk of mammary gland tumor development in mice.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Peter M. Carlson, Manasi Mohan, Matthew Rodriguez, Vladimir Subbotin, Claire X. Sun, Ravi B. Patel, Jen Birstler, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Zachary S. Morris, Amy K. Erbe, Paul M. Sondel
Summary: This study found that differences in depth of tumor implantation can lead to variations in response to immunotherapy. The mobile or fixed characteristics of tumors may predict response to therapy, regardless of intended implantation depth. This suggests that physical examination of tumor characteristics can ensure consistent tumor depth for immunotherapy experiments.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Public, Environmental & Occupational Health
Jessica M. Finlay, Jasdeep S. Kler, Brendan Q. O'Shea, Marisa R. Eastman, Yamani R. Vinson, Lindsay C. Kobayashi
Summary: This study identifies various coping strategies adopted by older adults during the early stages of the COVID-19 pandemic, including exercise, modifying routines, following public health guidelines, adjusting attitudes, and staying socially connected. While some coping strategies may be detrimental to health (e.g., overeating), the majority encourage personal improvement, positive adjustment, and overall well-being.
FRONTIERS IN PUBLIC HEALTH
(2021)
Article
Immunology
Peter M. Carlson, Manasi Mohan, Ravi B. Patel, Jen Birstler, Lauren Nettenstrom, Dagna Sheerar, Kathryn Fox, Matthew Rodriguez, Anna Hoefges, Reinier Hernandez, Chris Zahm, KyungMann Kim, Douglas G. McNeel, Jamey Weichert, Zachary S. Morris, Paul M. Sondel
Summary: Most shared resource flow cytometry facilities do not allow analysis of radioactive samples. Researchers are investigating a low-dose molecular targeted radionuclide therapy as an immunomodulator and need a reliable method for cryopreserving immune samples for flow cytometry analysis. Evaluating different fixation and cryopreservation protocols, it was found that freezing samples after all staining and fixation are completed most accurately matches noncryopreserved results.
JOURNAL OF IMMUNOLOGY
(2021)
Article
Public, Environmental & Occupational Health
Brendan Q. O'Shea, Jessica M. Finlay, Jasdeep Kler, Carly A. Joseph, Lindsay C. Kobayashi
Summary: The study estimated the prevalence of loneliness among US adults aged >= 55 during the early phase of the COVID-19 pandemic, finding that loneliness was most prevalent among those who reported depression, were not married or in a relationship, lived alone, and were unemployed at the onset of the pandemic.
PUBLIC HEALTH REPORTS
(2021)
Article
Cell Biology
Ravi B. Patel, Reinier Hernandez, Peter Carlson, Joseph Grudzinski, Amber M. Bates, Justin C. Jagodinsky, Amy Erbe, Ian R. Marsh, Ian Arthur, Eduardo Aluicio-Sarduy, Raghava N. Sriramaneni, Won Jong Jin, Christopher Massey, Alexander L. Rakhmilevich, David Vail, Johnathan W. Engle, Trang Le, Kyung Mann Kim, Bryan Bednarz, Paul M. Sondel, Jamey Weichert, Zachary S. Morris
Summary: The study demonstrates that delivering radiation semiselectively to tumors through targeted radionuclide therapy (TRT) can enhance response to immune checkpoint inhibitors (ICIs), leading to therapeutic efficacy and tumor-specific T cell memory in murine models. Combination of TRT and ICI activates production of proinflammatory cytokines, promotes tumor infiltration by CD8(+) T cells, and reduces metastases, suggesting a promising approach to improve response to ICIs for various tumor types.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Alexander A. Pieper, Alexander L. Rakhmilevich, Daniel Spiegelman, Ravi B. Patel, Jen Birstler, Won Jong Jin, Peter M. Carlson, Deborah H. Charych, Jacquelyn A. Hank, Amy K. Erbe, Willem W. Overwijk, Zachary S. Morris, Paul M. Sondel
Summary: The combination of local RT and BEMPEG showed a cooperative antitumor effect in multiple immunologically 'cold' tumor models, along with increased IL-2 receptor expression on peripheral T cells. Adding immune checkpoint blockade to RT+BEMPEG further strengthened the antitumor response in some models.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Megan A. Mullins, Jasdeep S. Kler, Marisa R. Eastman, Mohammed Kabeto, Lauren P. Wallner, Lindsay C. Kobayashi
Summary: This study found that self-reported cancer diagnoses in the US Health Retirement Study (HRS) have reasonable validity, especially when linked to Medicare claims. These findings have implications for population-based cancer and aging research.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Review
Environmental Sciences
Tyler A. Jacobson, Jasdeep S. Kler, Yeunook Bae, Jiexi Chen, Daniel T. Ladror, Ramsunder Iyer, Denise A. Nunes, Nathan D. Montgomery, Joachim D. Pleil, William E. Funk
Summary: Dried blood spot (DBS) sampling is a simple, cost-effective, and minimally invasive alternative for measuring exposure biomarkers in public health and epidemiological research. High-performing DBS methods have been developed and applied for detecting environmental exposures, but further research is needed for measuring other substances.
JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Michael C. Bellavia, Ravi B. Patel, Carolyn J. Anderson
Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer care, but many patients with poorly immunogenic tumors fail to benefit. External beam radiotherapy (EBRT) has been shown to synergize with ICI to prompt remarkable tumor regression and even eradication, but is not suitable for widely disseminated disease. Targeted radiopharmaceutical therapy (TRT) selectively delivers radiation to both the primary tumor and the metastatic sites, and has shown promising results, leading to regulatory approval of certain agents.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Oncology
Peter M. Carlson, Ravi B. Patel, Jen Birstler, Matthew Rodriquez, Claire Sun, Amy K. Erbe, Amber M. Bates, Ian Marsh, Joseph Grudzinski, Reinier Hernandez, Alexander A. Pieper, Arika S. Feils, Alexander L. Rakhmilevich, Jamey P. Weichert, Bryan P. Bednarz, Paul M. Sondel, Zachary S. Morris
Summary: The combination of external beam radiation therapy (EBRT) and intratumoral immunocytokine (IC) generates an effective in situ vaccine (ISV) against GD2-positive murine tumors. However, ISV does not produce an adequate response against distant tumors. Additional radiation therapy (RT) to all sites of disease may augment the antitumor responses to ISV.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Clinical Neurology
Marisa R. Eastman, Monica Ospina-Romero, Ashly C. Westrick, Jasdeep S. Kler, Medellena Maria Glymour, Ekland Abdiwahab, Lindsay C. Kobayashi
Summary: This study investigated whether an incident cancer diagnosis affects acute and long-term memory aging differently in older White and Black Americans. The results showed that Black participants experienced faster memory decline than White participants. In Whites, an incident cancer diagnosis was associated with acute memory decline, but not in Blacks. However, White cancer survivors had slower memory decline compared to cancer-free White adults, while this memory advantage was not observed among Black cancer survivors.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS
(2022)
Article
Biology
Reinier Hernandez, Kirsti L. Walker, Joseph J. Grudzinski, Eduardo Aluicio-Sarduy, Ravi Patel, Christopher D. Zahm, Anatoly N. Pinchuk, Christopher F. Massey, Ariana N. Bitton, Ryan J. Brown, Paul M. Sondel, Zachary S. Morris, Jonathan W. Engle, Christian M. Capitini, Jamey P. Weichert
COMMUNICATIONS BIOLOGY
(2019)
Article
Oncology
Derek A. Mumaw, Allison J. Hazy, Aleksander Vayntraub, Thomas J. Quinn, Kamran Salari, John H. Chang, Noah Kalman, Sanford Katz, James Urbanic, Robert H. Press, Arpi Thukral, Henry Tsai, George E. Laramore, Jason Molitoris, Carlos Vargas, Samir H. Patel, Craig Stevens, Rohan L. Deraniyagala
Summary: This study evaluated contralateral recurrences in patients with oropharyngeal squamous cell carcinoma who received unilateral proton beam therapy. The results showed a favorable contralateral neck failure rate that was comparable to photon irradiation.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Kangpyo Kim, Dongryul Oh, Jae Myoung Noh, Yang Won Min, Hong Kwan Kim, Yong Chan Ahn
Summary: This study suggests that hypofractionated radiation therapy alone is a feasible option for early stage esophageal squamous cell carcinoma patients. Particularly, in patients with tumor length < 3 cm, this treatment scheme shows favorable local control rates with low incidence of esophageal toxicities.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Lin Chen, Jing Li, Kunpeng Li, Jiang Hu, Qingjie Li, Chenglong Huang, Gaoyuan Wang, Na Liu, Linglong Tang
Summary: This study analyzed the probability of hearing impairment after radiotherapy for nasopharyngeal carcinoma and developed a predictive model, providing dose limitation suggestions to improve patients' quality of life.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Yiwei Yang, Jianxin Wang, Feng Gao, Zhen Liu, Tangzhi Dai, Haowen Zhang, Hongyu Zhu, Tingting Wang, Dexin Xiao, Kui Zhou, Zheng Zhou, Dai Wu, Xiaobo Du, Sen Bai
Summary: This paper provides a comprehensive description of the current status of PARTER, which is the first experimental FLASH platform utilizing megavoltage X-rays. It showcases the reliable performance and stability of the dosimeters and monitors used in PARTER, as well as the satisfactory dose distribution and characteristics of the FLASH X-rays. The platform effectively meets the requirements of preclinical research on megavoltage X-ray FLASH and undergoes continuous upgrades.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Maria Thor, Kelly Fitzgerald, Aditya Apte, Jung Hun Oh, Aditi Iyer, Otasowie Odiase, Saad Nadeem, Ellen D. Yorke, Jamie Chaft, Abraham J. Wu, Michael Offin, Charles B. Simone Ii, Isabel Preeshagul, Daphna Y. Gelblum, Daniel Gomez, Joseph O. Deasy, Andreas Rimner
Summary: The purpose of this study was to identify predictors of disease progression in early-stage non-small cell lung cancer (NSCLC) patients after receiving definitive stereotactic body radiation therapy (SBRT). The results showed that tumor diameter and SUVmax were the most frequently reported features associated with progression/survival, and a re-fitted model including these two features had the best performance.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Yong-Qiao He, Tong-Min Wang, Da-Wei Yang, Wen-Qiong Xue, Chang-Mi Deng, Dan-Hua Li, Wen-Li Zhang, Ying Liao, Ruo-Wen Xiao, Lu-Ting Luo, Hua Diao, Xia-Ting Tong, Yan-Xia Wu, Xue-Yin Chen, Jiang-Bo Zhang, Ting Zhou, Xi-Zhao Li, Pei-Fen Zhang, Xiao-Hui Zheng, Shao-Dan Zhang, Ye-Zhu Hu, Guan-Qun Zhou, Jun Ma, Ying Sun, Wei-Hua Jia
Summary: In this study, researchers aimed to establish a predictive model for radiation-induced brain injury (RBI) in nasopharyngeal carcinoma (NPC) patients by incorporating clinical factors and newly developed genetic variants. They conducted a large-scale retrospective study and a genome-wide association study to develop a polygenic risk score (PRS) for RBI risk prediction. The results showed that the PRS, combined with clinical factors, improved the accuracy of RBI risk stratification and suggested personalized radiotherapy.
RADIOTHERAPY AND ONCOLOGY
(2024)
Review
Oncology
Xiaoyong Xiang, Zhe Ji, Jing Jin
Summary: A review of studies suggests that brachytherapy as a salvage therapy for recurrent glioblastoma shows acceptable safety and good post-treatment clinical efficacy for selected patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
M. Berbee, C. T. Muijs, F. E. M. Voncken, L. Wee, M. Sosef, B. van Etten, J. W. van Sandick, F. A. R. M. Warmerdam, J. J. de Haan, E. Oldehinkel, J. M. van Dieren, L. Boersma, J. A. Langendijk, A. van der Schaaf, J. B. Reitsma, E. Schuit
Summary: This study externally validated a model for predicting 2-year total mortality in lung cancer patients in esophageal cancer patients. The intercept and/or slope of the original model needed adjustment to achieve good performance in esophageal cancer patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Dominique Reijtenbagh, Jeremy Godart, Joan Penninkhof, Sandra Quint, Andras Zolnay, Jan-Willem Mens, Mischa Hoogeman
Summary: This study compared the performance of the current PotD strategy with non-adaptive and fully online-adaptive techniques in the treatment of cervical cancer patients. The findings show that the PotD protocol is effective in improving normal tissue sparing compared to no adaptation, while fully online-adaptive approaches can further reduce target volume but come with a more complex workflow.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Albrecht Weiss, Steffen Loeck, Ting Xu, Zhongxing Liao, Aswin L. Hoffmann, Esther G. C. Troost
Summary: Traditional models for predicting radiation pneumonitis may not be applicable to non-small cell lung cancer patients treated with passively-scattered proton therapy. The use of effective alpha/beta parameter can predict the occurrence of radiation pneumonitis in these patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Z. A. R. Gouw, J. Jeong, A. Rimner, N. Y. Lee, A. Jackson, A. Fu, J-j. Sonke, J. O. Deasy
Summary: This study investigates the effectiveness of non-uniform fractionation schedules in radiotherapy for early-stage non-small cell lung cancer. Through modeling, optimized schedules are proposed to minimize local failures and toxicity risk. The results suggest that non-standard primer shot fractionation can reduce hypoxia-induced radioresistance and improve treatment outcomes.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Sara Ronchi, Alessandro Cicchetti, Maria Bonora, Rossana Ingargiola, Anna Maria Camarda, Stefania Russo, Sara Imparato, Paolo Castelnuovo, Ernesto Pasquini, Piero Nicolai, Mohssen Ansarin, Michele Del Vecchio, Marco Benazzo, Ester Orlandi, Barbara Vischioni
Summary: This study evaluates the efficacy and toxicity of carbon ion radiotherapy (CIRT) in locally advanced head and neck mucosal melanoma patients. The results show that CIRT is safe and effective in treating the local region, and immunotherapy after relapse can improve overall survival. However, further prospective trials are needed to assess the role of targeted/immune- systemic therapy in this disease.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Dominik Wawrzuta, Justyna Klejdysz, Marzanna Chojnacka
Summary: This study analyzed articles about radiation oncology published in The New York Times since its inception in 1851, and identified changes in media sentiment and prevalent themes related to radiotherapy. The findings suggest an increasing negative sentiment in media coverage towards radiotherapy, with a shift towards reporting treatment errors, toxicity, and ineffectiveness.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Elaine Limkin, Pierre Blanchard, Benjamin Lacas, Jean Bourhis, Mahesh Parmar, Lisa Licitra, Quynh-Thu Le, Sue S. Yom, Catherine Fortpied, Johannes Langendijk, Jan B. Vermorken, Jacques Bernier, Jens Overgaard, Jonathan Harris, Jean-Pierre Pignon, Anne Auperin
Summary: This study investigated the impact of season of radiotherapy on the outcomes of head and neck squamous cell cancer patients. The results showed that the season of radiotherapy did not have any significant effect on patient outcomes.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Fabio L. Cury, Gustavo A. Viani, Andre G. Gouveia, Camila V. S. Freire, Gabriel de A. Grisi, Fabio Y. Moraes
Summary: In limb-sparing treatment of soft tissue sarcoma patients, a 5-day course of preoperative radiotherapy results in high local control and favorable R0 margins, with acceptable complication rates, particularly for patients receiving higher biological equivalent doses.
RADIOTHERAPY AND ONCOLOGY
(2024)